GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline pleads guilty to promoting Paxil and Wellbutrin off-label and failing to report Avandia safety data to FDA; civil portion of settlement resolves off-label and kickback allegations involving nine products. New corporate integrity agreement gives OIG authority to require a recall.
You may also be interested in...
AmerisourceBergen Settlement On Injectable Drug Repackaging Includes Forfeiture Of Exec Pay
Corporate integrity agreement attached to second DOJ settlement over repackaging of injectable cancer drugs would require recoupment of exec performance pay following misconduct.
FDA Label Decisions On Paxil Don't Deter Verdict Against GSK In Suicide Case
Chicago jury finds GSK failed to adequately warn about risk of suicidal behavior in patients over age 24 taking paroxetine; GSK argued that FDA had found no increased risk in this population.
FDA Label Decisions On Paxil Don't Deter Verdict Against GSK In Suicide Case
Chicago jury finds GSK failed to adequately warn about risk of suicidal behavior in patients over age 24 taking paroxetine; GSK argued that FDA had found no increased risk in this population.